CMRX - Chimerix Price-to-Projected Revenue Ratio

Chimerix Inc (CMRX) - corporate logo

The absence of dividends is driven by biosecurity costs and the risk of test failures. The forward P/S ratio serves as an indicator of market confidence, where 3785.30 determines the latest valuation metric. US government contracts for antivirals guarantee stability. However, the binary outcomes of ONC201 trials and rapid R&D cash burn place significant pressure on the balance sheet of Chimerix, Inc. (CMRX).

Chimerix Inc. - CMRX Projected Price to Revenue (period 07/04/2022 - 04/26/2025)

Comprehensive metric breakdowns and analytics for Chimerix Inc (CMRX)

- market price and analyst price targets:
Price Chart Chimerix|CMRX - Price Target Chart
- market capitalization statistics:
Market Value Chimerix Inc|CMRX - Total Enterprise Value
- book value of equity indicators:
Book Value per Share Chimerix|CMRX - Book Value of Business|Market Cap to Net Assets Ratio chimerix.com|CMRX - Company Assets
- debt and liquidity data:
Total Debt to Equity Ratio Chimerix, Inc.|CMRX - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio Chimerix, Inc.|CMRX - Company Cumulative Indebtedness|Debts to Book Capitalization Chimerix Inc|CMRX - Company Long-Term Loans and Borrowings|Company Short-Term Debts Chimerix|Quick Liquidity chimerix.com
- financial results and valuation multiples details:
CMRX - Final Profit|Projected Future Earnings Chimerix, Inc.|CMRX - P/E Multiple|Future Price to Earnings Chimerix, Inc|CMRX - Market Cap to Earnings and Growth Ratio|Enterprise Value to EBITDA Ratio Chimerix Inc|CMRX - Profit before interest, taxes and amortization|Net earnings per share (EPS TTM) Chimerix|CMRX - Net earnings per share for the last 12 months|Quarterly EPS earnings growth chimerix.com|CMRX - Earnings per share increase in current year|Earnings growth forecast for next year Chimerix, Inc.
- revenue and sales proceeds data:
CMRX - Company Gross Revenue|Company Projected Revenue Chimerix|CMRX - Market Cap to Revenue|Forward P/S Multiple Chimerix Inc
General company analysis:Chimerix CMRX
Manufactured products of chimerix.com

The monopoly status of Chimerix, Inc. (CMRX) orphan drugs enables the company to set high therapy prices, which directly impacts future cash flows. The forward P/S multiple trend correlates the current market value of Chimerix, Inc. (CMRX) with expected revenue, allowing investors to assess whether the exclusivity premium for the drugs is justified and to determine the risk of overpaying for sales growth potential.

Key competitors

Price-to-Projected Revenue Ratio Incyte INCY|Hutchison MediPharma - Price-to-Projected Revenue Ratio|NUVB - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Day One Biopharmaceuticals Inc|MNPR: Forward P/S Multiple|Projected Price to Revenue inhibrx.com INBX|Forward Price-to-Revenue Multiple IMAB|Market Cap to Future Revenue Ratio Fennec Pharma FENC|Forward Price-to-Revenue Multiple HRTX (Heron Therapeutics)|NVCT (Nuvectis Pharma, Inc) - Forward Price to Sales|Coherus Biosciences - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio CRBP (corbuspharma.com)|Cardiff Oncology Corp - Forward P/S Multiple|Forward Price to Sales BYSI (BeyondSpring, Inc.)|BCAB: Forward P/S Multiple|Market Cap to Future Revenue Ratio Lixte Biotechnology, Inc. (LIXT)|Price-to-Projected Revenue Ratio Citius Pharmaceuticals Inc.|CLRB: Forward Price to Sales|Forward P/S Multiple BLRX|Forward P/S Multiple Can-Fite BioPharma Ltd (CANF)|Price-to-Projected Revenue Ratio Aprea Therapeutics, Inc. APRE|KZIA (Kazia Therapeutics Ltd) - Future Price to Revenue|SLXN: Forward Price-to-Revenue Multiple|Market Cap to Future Revenue Ratio NuCana plc|CYCC: Forward P/S Multiple|Forward Price-to-Revenue Multiple G1 Therapeutics|KRON (Kronos Bio Corp) - Forward P/S Multiple|KTRA: Forward Price to Sales|Forward P/S Multiple ONCT|Market Cap to Expected Sales Ratio portagebiotech.com